RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Debora Fumagalli, David Venet, Michail Ignatiadis, Hatem A Azim, Marion Maetens, Francoise Rothe, Roberto Salgado, Ian Bradbury, Lajos Pusztai, Nadia Harbeck, Henry Gomez, Tsai-Wang Chang, Maria Antonia Coccia-Portugal, Serena Di Cosimo, Evandro de Azambuja, Lorena de la Pena, Paolo Nuciforo, Jan C Brase, Jens Huober, Jose Baselga Show all
JAMA Oncology | AMER MEDICAL ASSOC | Published : 2017
The NeoALTTO study and this substudy were sponsored by GlaxoSmithKline; lapatinib is an asset of Novartis AG as of March 2, 2015. Dr Venet's activity is partly supported by a grant of the Region Wallonne.